Effects of diabetes and smoking on ticagrelor's effectiveness in heart attack patients
Ndividualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
This study is testing how diabetes and smoking affect the effectiveness of a heart medication called ticagrelor in heart attack patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT05911659 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare how diabetes and smoking individually and combined affect the antiplatelet activity of ticagrelor in patients experiencing acute myocardial infarction who are undergoing primary percutaneous coronary intervention (PCI). A total of sixty patients will be categorized into four groups based on their diabetes and smoking status, with each group receiving a loading dose of ticagrelor. The study will measure platelet reactivity index (PRI) and maximum platelet aggregation (MPA) 24 hours after the loading dose to assess antiplatelet efficacy. The findings could provide insights into optimizing treatment strategies for patients with varying risk factors.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with acute coronary syndrome undergoing PCI who have varying statuses of diabetes and smoking.
Not a fit: Patients with a history of severe bleeding, thrombocytopenia, or those on other antiplatelet medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment approaches for heart attack patients, improving their outcomes based on individual risk factors.
How similar studies have performed: While the effects of diabetes and smoking on platelet reactivity have been studied, this specific combination and its impact on ticagrelor's efficacy in acute myocardial infarction patients is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Acute coronary syndrome (ACS) undergoing PCI Exclusion Criteria: Patients who had a history of severe bleeding, serious bleeding tendency, history of intracranial hemorrhage, signs of active bleeding, thrombocytopenia, uncontrolled hypertension, hypersensitivity to the used drugs (clopidogrel or ticagrelor), concomitant use of strong CYP inducers or inhibitors, and/or severe liver disorders were excluded from the study. Patients with previous history of coronary artery disease, previous PCI or patients administering other antiplatelets were excluded from the current study.
Where this trial is running
Cairo
- Faculty of medicine of girls, Cardiology department, Al-Azhar University in Cairo — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Nasima M El-Kenany, Ph.D
- Email: mina.moharebmedicinewolters@gmail.com
- Phone: 01007844927
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.